Dr. Tyna Moore · 2026-01-23 · Tyna Moore (host), Tyler Panzner
Why Supplements Make Some Women Feel Worse (And What Actually Works) | Dr Tyler Panzner Ep 245
35 research-tied claims examined: 4 contradicted 8 overstated 22 supported 1 unverified
4 Contradicted by research
Rayaldee is a pre-activated vitamin D prescribed for multiple sclerosis.
"They prescribe that pre-activated vitamin D for multiple sclerosis. It's called Rayaldee." (said at 0:16:56)
Rayaldee is an extended-release formulation of calcifediol (25-hydroxyvitamin D3, a pro-hormone/intermediate metabolite). It is approved and prescribed for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency, not for multiple sclerosis. Although calcifediol and vitamin D supplementation have been investigated experimentally in multiple sclerosis research trials, Rayaldee is neither indicated nor standardly prescribed for multiple sclerosis.
- context: Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple scleros… (Multiple sclerosis and related disorders 2024) · cited 1x in the literature
"While both groups showed an overall trend towards improved cognitive function at the end of the study, the calcifediol group exhibited greater improvements in most cognitive tests. However, the trial had no significant beneficial effects on MS relapse, EDSS score, quality of life, or fatigue in either group, the calcifediol or cholecalciferol." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: New insights into the management of secondary hyperparathyroidism in non-dialysis dependen… (Journal of nephrology 2026)
"This article examines the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease (NDD-CKD) patients in Switzerland, with a focus on optimizing bone and mineral health in CKD stages 3-4... A treatment algorithm incorporating extended-release calcifediol, as well as insights from KDIGO (Kidney Disease: Improving Global Outcomes) for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), are presented to refine therapeutic approaches." (abstract, passage verified)
pubmedfull study (doi)
Stress and adrenaline trigger the release of histamine.
"And we need to remember adrenaline, stress itself releases histamine, right?" (said at 0:59:30)
The claim states that adrenaline and stress trigger the release of histamine. While psychological and physiological stress can stimulate mast cell degranulation and histamine release via neuropeptides and neuroendocrine pathways (such as corticotropin-releasing hormone and substance P), adrenaline (epinephrine) does the opposite: it is a potent mast cell stabilizer that suppresses and inhibits histamine release via beta-2 adrenergic receptors. Because of this inhibitory action on mast cell mediator release and its physiological counter-effects, adrenaline is used as the first-line medical treatment for acute histamine-mediated allergic reactions and anaphylaxis.
- contradicts: beta2-Adrenoceptor-mediated suppression of human intestinal mast cell functions is caused … (European journal of immunology 2005) · cited 38x in the literature
"beta2AR activation by epinephrine, norepinephrine, and salbutamol suppressed the IgE receptor-dependent release of histamine, lipid mediators, and TNF-alpha, and inhibited SCF-dependent MC proliferation and migration." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Prazosin Potentiates Mast Cell-Stabilizing Property of Adrenaline. (Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2024) · cited 5x in the literature
"Adrenaline quickly inhibits the release of histamine from mast cells." (abstract, background, passage verified)
pubmedfull study (doi)
Studies of traditional African tribes show natural vitamin D levels over 150 ng/mL.
"there were studies of tribes in Africa, their natural levels I think are over 150 nanograms per milliliter, right? And naked in the sun." (said at 1:03:00)
Studies measuring serum 25-hydroxyvitamin D concentrations in traditionally living East African populations (such as the Maasai pastoralists and Hadzabe hunter-gatherers) report average levels of approximately 115 nmol/L (~46 ng/mL), with individual values ranging from 58 to 171 nmol/L (~23 to 68 ng/mL). The speaker appears to have confused nmol/L with ng/mL; natural levels are well below 150 ng/mL (which would equal ~375 nmol/L, a level associated with vitamin D toxicity).
Participants adhering to lifestyle and behavioral weight management programs achieved superior results compared to those using weight-loss medications alone.
"So there was the weight loss medications, and then there's behavioral weight management programs. The people doing the lifestyle did better [music] than the people doing just the medications." (said at 1:11:27)
Randomized controlled trial evidence demonstrates that weight-loss medications alone typically yield greater weight loss than lifestyle/behavioral interventions alone, and newer anti-obesity medications like semaglutide produce substantially greater weight loss than intensive lifestyle modification.
In a seminal 1-year randomized trial of 224 adults with obesity (Wadden et al., 2005, PMID: 16291981), participants treated with lifestyle modification alone lost a mean of 6.7 kg, whereas those receiving medication (sibutramine) plus brief primary care visits lost 7.5 kg, and those receiving intensive combined medication plus lifestyle therapy lost 12.1 kg.
Furthermore, modern glucagon-like peptide-1 (GLP-1) receptor agonists achieve significantly higher weight loss than intensive behavioral therapy. In the STEP 3 clinical trial (Wadden et al., 2021, PMID: 33625476), adults receiving intensive behavioral therapy (30 counseling sessions plus initial low-calorie diet) with placebo lost a mean of 5.7% of body weight at 68 weeks, whereas adding semaglutide (2.4 mg) increased total weight loss to 16.0%. In the STEP 1 trial (PMID: 33567185), semaglutide with standard lifestyle advice achieved a mean weight reduction of 14.9% (15.3 kg) versus 2.4% (2.6 kg) for placebo/lifestyle alone. Thus, claims that participants in lifestyle management programs achieve superior weight loss compared to those taking weight-loss medications alone are contradicted by clinical trial evidence.
- contradicts: Randomized trial of lifestyle modification and pharmacotherapy for obesity. (The New England journal of medicine 2005) · cited 799x in the literature
"At one year, subjects who received combined therapy lost a mean (+/-SD) of 12.1+/-9.8 kg, whereas those receiving sibutramine alone lost 5.0+/-7.4 kg, those treated by lifestyle modification alone lost 6.7+/-7.9 kg, and those receiving sibutramine plus brief therapy lost 7.5+/-8.0 kg (P<0.001)." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Once-Weekly Semaglutide in Adults with Overweight or Obesity. (The New England journal of medicine 2021) · cited 4897x in the literature
"The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points" (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therap… (JAMA 2021) · cited 1056x in the literature
"At week 68, the estimated mean body weight change from baseline was -16.0% for semaglutide vs -5.7% for placebo (difference, -10.3 percentage points [95% CI, -12.0 to -8.6]; P < .001)." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.